--- title: 'Life Sciences Daily Summary: What Happened on November 5, 2026' headline: Boehringer licenses six cancer programs in deal with up to $7 billion in milestones description: BioNTech raised its 2026 revenue outlook amid mixed cancer-trial results. Alethio and T-Therapeutics raised funds, and Evommune licensed an autoimmune candidate. url: https://thebench.bio/news/summaries/2026-11-05 topic: all date: '2026-11-05' covers: - '2026-11-05' date_published: '2026-11-05T12:11:51Z' date_modified: '2026-11-05T12:11:51Z' tags: - Industry - Funding sources: 6 publisher: TheBench.Bio --- # Life Sciences Daily Summary: What Happened on November 5, 2026 **Boehringer licenses six cancer programs in deal with up to $7 billion in milestones** BioNTech raised its 2026 revenue outlook amid mixed cancer-trial results. Alethio and T-Therapeutics raised funds, and Evommune licensed an autoimmune candidate. ## Today in brief Boehringer Ingelheim licensed six preclinical cancer programs from Sino Biopharmaceutical for $358 million in upfront and near-term payments, with up to $7 billion more possible in milestones. [1] BioNTech increased its 2026 revenue forecast and reported both gains and setbacks across its cancer pipeline. [2] China approved Bayer’s sevabertinib as a first-line treatment for advanced lung cancer with HER2 mutations. [3] Alethio raised $90 million for blood-cancer programs, T-Therapeutics raised $133 million for two T-cell engager programs, and Evommune licensed an autoimmune candidate in a deal worth up to about $1.1 billion. [4] [5] [6] ## Boehringer adds six early cancer programs through China deal Boehringer Ingelheim agreed to license six preclinical cancer programs from Sino Biopharmaceutical, including antibody-drug conjugates and T-cell engagers, molecules designed to direct immune cells toward targets. [1] Sino will receive $358 million in upfront and near-term payments and could earn up to $7 billion in milestones, plus tiered royalties on sales. [1] Sino will lead early development. Boehringer can exercise options after clinical milestones. [1] Boehringer’s potential rights to four programs exclude mainland China, Hong Kong, and Macau. Rights to the other two could be worldwide. [1] LaNova Medicines supplied five candidates and Tide Pharmaceutical supplied one. [1] ## BioNTech lifts revenue outlook as cancer pipeline delivers mixed results BioNTech raised its 2026 revenue forecast to €1.7 billion–€1.9 billion, from a previous range of €1.6 billion–€1.9 billion. [2] Third-quarter revenue was €1.289 billion and net profit was €184.5 million. The company recorded a €1.168 billion net loss for the first nine months of the year. [2] BioNTech ended the quarter with €16.2 billion in cash and liquid securities. [2] The Bristol Myers Squibb collaboration contributed €613 million in third-quarter revenue, exceeding the €554 million from COVID-19 vaccines after a contractual payment became recognizable when a termination option expired. [2] The deal includes another $2 billion in non-contingent payments through 2028, plus potential milestones of up to $7.6 billion. [2] The first, non-pivotal portion of gotistobart’s Phase 3 study showed a statistically significant overall-survival improvement over chemotherapy. BioNTech said median survival was nearly twice as long. [2] BioNTech expects interim results from the study’s second portion before the end of 2026, subject to an initial review by an independent monitoring committee. [2] A Phase 3 trial of trastuzumab pamirtecan met its primary progression-free-survival endpoint, but BioNTech described the effect as moderate and reported more interstitial lung disease, including severe and fatal cases. [2] BNT113 did not significantly improve progression-free survival when added to pembrolizumab. A Phase 2 colorectal cancer trial of autogene cevumeran is ending early. [2] A separate Phase 2 autogene cevumeran study in pancreatic cancer is continuing after recruitment ended in August. [2] ## China clears Bayer’s sevabertinib for first-line lung cancer treatment China’s National Medical Products Administration approved Bayer’s sevabertinib for adults with advanced, unresectable or metastatic non-small cell lung cancer with activating HER2 mutations, including people not previously treated for the disease. [3] The approval is based on a cohort of 73 previously untreated patients in the ongoing Phase 1/2 SOHO-01 study. The objective response rate was 75%, and 6% of patients had a complete response. [3] Among responders, 73% maintained their response for at least six months. [3] A Phase 3 trial is testing sevabertinib against standard therapy in previously untreated patients. The early response results do not establish whether it improves progression-free or overall survival over standard care. [3] Boehringer Ingelheim’s zongertinib received China’s first-line authorization in May 2026. Sevabertinib already had first-line authorization in the United States and Japan. [3] ## Alethio raises $90 million for blood-cancer antibody Alethio Therapeutics raised a $90 million Series A co-led by Sofinnova Partners and RA Capital to advance ATX-011 and other drug candidates. [4] The company plans to develop ATX-011, an antibody targeting G6B, first for essential thrombocythemia, a type of myeloproliferative neoplasm. [4] Research using samples from more than 100 people with myeloproliferative neoplasms found G6B on abnormal stem cells but not on healthy blood stem cells. [4] In a study of two nonhuman primates, platelet counts fell 80% after 96 hours and later recovered as the antibody cleared. Researchers reported no effects on hemoglobin or white blood cells. [4] Alethio’s chief executive expects enrollment to start during the first six months of 2028, pending regulatory processes. [4] ## T-Therapeutics raises $133 million for two experimental programs T-Therapeutics raised $133 million in a Series B to advance two experimental T-cell engager programs toward clinical proof of concept. [5] The company is developing the programs for cancer and autoimmune diseases. [5] Its platform uses engineered mice to find human T-cell receptors, which the company incorporates into bispecific molecules that bind a disease-associated target and CD3 on T cells. [5] Advent Life Sciences and British Business Bank jointly led the financing. Johnson & Johnson Innovation, Samsara BioCapital, M-Ventures, and Eli Lilly were among the new investors. [5] ## Evommune licenses autoimmune candidate from Hinova Evommune obtained an exclusive license from Hinova for EVO570 in territories outside Greater China, covering development, manufacturing, and commercialization. [6] The deal is valued at up to about $1.1 billion. [6] Evommune will pay $30 million upfront, comprising $20 million in cash and $10 million in pre-funded warrants. Further payments depend on development, regulatory, and commercial milestones. [6] EVO570 is a molecular glue degrader designed to target VAV1 signaling, a pathway involved in immune-cell activity. [6] A Phase 1 study is scheduled to assess safety, pharmacokinetics, and target engagement. Evommune plans to report findings and start a Phase 2 rheumatoid arthritis trial in 2027. [6] ## The day in numbers - **$7 billion**: Maximum potential milestone payments in Boehringer Ingelheim’s deal for six preclinical cancer programs. [1] - **€1.7 billion–€1.9 billion**: BioNTech’s updated revenue forecast for 2026. [2] - **75%**: Objective response rate among 73 previously untreated patients in the sevabertinib cohort used for China’s first-line approval. [3] - **$90 million**: Alethio Therapeutics’ Series A financing. [4] - **$133 million**: T-Therapeutics’ Series B financing. [5] - **$30 million**: Upfront payment in Evommune’s license deal for EVO570. [6] ## Sources 1. [Boehringer secures six Chinese cancer programs in deal worth up to $7B](), European Biotechnology, 2026-11-05 2. [BioNTech: BMS becomes a revenue mainstay — but the pipeline still has to deliver](), European Biotechnology, 2026-11-05 3. [Bayer closes the gap with Boehringer in China’s lung cancer race](), European Biotechnology, 2026-11-05 4. [Oxford spinout Alethio raises $90M Series A for chronic blood cancer trials](), European Biotechnology, 2026-11-05 5. [T-Therapeutics raises $133M to bring TCR bispecifics into clinic](), European Biotechnology, 2026-11-05 6. [Evommune signs $1.1bn licence deal with Hinova for EVO570](), Pharmaceutical Technology, 2026-11-05 --- TheBench.Bio wrote this from the reporting cited above, with a language model drafting and editing. [1]: [2]: [3]: [4]: [5]: [6]: